keyword
https://read.qxmd.com/read/38654374/severe-enduring-anorexia-nervosa-se-an-treatment-options-and-their-effectiveness-a-review-of-literature
#1
REVIEW
Federica Marcolini, Alessandro Ravaglia, Silvia Tempia Valenta, Giovanna Bosco, Giorgia Marconi, Diana De Ronchi, Anna Rita Atti
INTRODUCTION:  For nearly 20% of patients diagnosed with Anorexia Nervosa (AN), the eating disorder (ED) is prolonged and becomes long-lasting. It has been reported that patients diagnosed with Severe Enduring Anorexia Nervosa (SE-AN) have worse ED symptoms, higher rates of lifetime hospitalization, and lower psychosocial well-being compared to patients with shorter disease duration. OBJECTIVES:  This review aims to describe the treatments proposed to date and their effectiveness on SE-AN-related outcomes...
April 23, 2024: Journal of Eating Disorders
https://read.qxmd.com/read/38622003/orexinergic-receptor-antagonists-as-a-new-therapeutic-target-to-overcome-limitations-of-current-pharmacological-treatment-of-insomnia-disorder
#2
JOURNAL ARTICLE
Cecilio Álamo, Jerónimo Sáiz Ruiz, Cristina Zaragozá Arnáez
Insomnia disorder is a common condition that is considered a risk factor for multiple physical and mental disorders, contributing to reduced quality of life and increased healthcare expenditures. Although cognitive behavioral therapy (CBT) is typically recommended as the primary intervention, its accessibility is hindered by limited resources, prompting the prevalent use of pharmacological interventions as the primary treatment in clinical settings. This study reviews the benefits and risks of current pharmacological treatments for insomnia, with special reference to the orexinergic system as a novel therapeutic target for treatment...
April 2024: Actas Españolas de Psiquiatría
https://read.qxmd.com/read/38433233/a-phase-iii-multisite-randomised-controlled-trial-to-compare-the-efficacy-of-cannabidiol-to-placebo-in-the-treatment-of-cannabis-use-disorder-the-cbd-cud-study-protocol
#3
JOURNAL ARTICLE
Anjali K Bhardwaj, Llew Mills, Michael Doyle, Arshman Sahid, Mark Montebello, Lauren Monds, Shalini Arunogiri, Paul Haber, Valentina Lorenzetti, Dan I Lubman, Peter Malouf, Mary E Harrod, Adrian Dunlop, Tom Freeman, Nicholas Lintzeris
BACKGROUND: Cannabis use disorder (CUD) is increasingly common and contributes to a range of health and social problems. Cannabidiol (CBD) is a non-intoxicating cannabinoid recognised for its anticonvulsant, anxiolytic and antipsychotic effects with no habit-forming qualities. Results from a Phase IIa randomised clinical trial suggest that treatment with CBD for four weeks reduced non-prescribed cannabis use in people with CUD. This study examines the efficacy, safety and quality of life of longer-term CBD treatment for patients with moderate-to-severe CUD...
March 4, 2024: BMC Psychiatry
https://read.qxmd.com/read/38323679/cognitive-behavioural-therapy-without-medication-for-schizophrenia
#4
REVIEW
Irene Bighelli, Oğulcan Çıray, Nurul Husna Salahuddin, Stefan Leucht
BACKGROUND: Cognitive behavioural therapy (CBT) can be effective in people with schizophrenia when provided in combination with antipsychotic medication. It remains unclear whether CBT could be safely and effectively offered in the absence of concomitant antipsychotic therapy. OBJECTIVES: To investigate the effects of CBT for schizophrenia when administered without concomitant pharmacological treatment with antipsychotics. SEARCH METHODS: We conducted a systematic search on 6 March 2022 in the Cochrane Schizophrenia Group's Study-Based Register of Trials, which is based on CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, PubMed, ClinicalTrials...
February 7, 2024: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/38186501/the-role-of-low-dose-quetiapine-in-the-treatment-of-somatic-symptom-disorder-a-case-report
#5
Shayranisse Pagan Cruz, Patricia M Guiribitey, Ginger Shupe
Somatic symptom disorder (SSD) involves physical symptoms like palpitations, pain, weakness, dizziness, and pseudo-neurological symptoms. These symptoms are accompanied by excessive thoughts, emotions, and behaviors related to the symptom, causing significant distress and impairment lasting at least six months. They may not be explained by any underlying medical conditions. SSD can be resistant to standard treatment modalities like Cognitive Behavioral Therapy (CBT), Selective Serotonin Reuptake Inhibitors (SSRIs), and Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)...
December 2023: Curēus
https://read.qxmd.com/read/38090708/clinical-case-report-considerable-improvement-of-severe-and-difficult-to-treat-obsessive-compulsive-disorder-with-comorbid-depression-under-treatment-with-esketamine-and-concomitant-psychotherapy
#6
Alexander Kaltenboeck, Elisa Foerster, Sabrina Strafner, Ulrike Demal, Nilufar Mossaheb, Fabian Friedrich
A 28-year-old man was admitted to our psychiatric ward with severe obsessive-compulsive disorder (OCD) and comorbid depression. At intake, obsessive-compulsive symptoms were present most time of the day and were related to an intense fear of causing interpersonal misunderstandings. Various treatment attempts, including cognitive-behavioural therapy (CBT) with exposure and response prevention (ERP), selective serotonin reuptake inhibitors, clomipramine, and add-on antipsychotics were either ineffective and/or were not tolerated, and the patient's condition worsened progressively...
2023: Frontiers in Psychiatry
https://read.qxmd.com/read/37956131/brazilian-psychiatric-association-guidelines-for-the-treatment-of-generalized-anxiety-disorder-gad-pharmacological-and-psychotherapy-approach-perspectives
#7
JOURNAL ARTICLE
Leonardo Baldaçara, Ana Beatriz Paschoal, Aldo Felipe Pinto, Fabiano Franca Loureiro, Luiz Antonio Vesco Gaiotto, Diogo de Lacerda Veiga, Thales Marcon Almeida, Diogo Cesar Dos Santos, Leandro Fernandes Malloy-Diniz, Marcelo Feijó de Mello, Andrea Feijó de Mello, Marsal Sanches, Lucas Marques Gandarela, Márcio Antonini Bernik, Antonio E Nardi, Antônio Geraldo da Silva, Ricardo R Uchida
OBJECTIVE: To combine elements of a systematic review and critical review to produce best evidence synthesis for the treatament of GAD. METHOD: There was included systematic reviews, metanalysis, and randomized controlled trials. Descriptor used was "generalized anxiety disorder", resulting in 4860 articles and 7 other studies, of which 59 were selected. RESULTS: Antidepressants and benzodiazepines are indicated, as well as pregabalin. From, atypical antipsychotics quetiapine has been studied...
November 13, 2023: Revista Brasileira de Psiquiatria
https://read.qxmd.com/read/37748987/-recent-developments-in-the-modeling-and-psychological-management-of-persecutory-ideation
#8
JOURNAL ARTICLE
Stéphane Raffard, Alexandre de Connor, Daniel Freeman, Catherine Bortolon
Persecutory ideas are a major clinical problem and are associated with impaired functioning, reduced compliance with medication and increased risk of hospitalization. Persecutory ideation is defined as the false conviction that others are threatening or conspiring against one. Although persecutory delusions are mainly described and experienced in schizophrenia spectrum disorders, they also occur in other neurological and psychiatric diagnoses including Alzheimer disease, epilepsy, depression, mania, dementia and post-traumatic stress disorder...
September 23, 2023: L'Encéphale
https://read.qxmd.com/read/37610143/specific-psychological-therapies-versus-other-therapies-or-no-treatment-for-severe-and-enduring-anorexia-nervosa
#9
REVIEW
James Zhu, Phillipa J Hay, Yive Yang, Daniel Le Grange, J Hubert Lacey, Sanja Lujic, Caroline Smith, Stephen Touyz
BACKGROUND: Anorexia nervosa is a psychological condition characterised by self-starvation and fear or wait gain or other body image disturbance. The first line of treatment is specific psychological therapy; however, there is no consensus on best practice for treating people who develop severe and enduring anorexia nervosa (SEAN). Notably, there is no universal definition of SEAN. OBJECTIVES: To evaluate the benefits and harms of specific psychological therapies for severe and enduring anorexia nervosa compared with other specific therapies, non-specific therapies, no treatment/waiting list, antidepressant medication, dietary counselling alone, or treatment as usual...
August 23, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/37048577/alliance-for-sleep-clinical-practice-guideline-on-switching-or-deprescribing-hypnotic-medications-for-insomnia
#10
REVIEW
Nathaniel F Watson, Ruth M Benca, Andrew D Krystal, William V McCall, David N Neubauer
Determining the most effective insomnia medication for patients may require therapeutic trials of different medications. In addition, medication side effects, interactions with co-administered medications, and declining therapeutic efficacy can necessitate switching between different insomnia medications or deprescribing altogether. Currently, little guidance exists regarding the safest and most effective way to transition from one medication to another. Thus, we developed evidence-based guidelines to inform clinicians regarding best practices when deprescribing or transitioning between insomnia medications...
March 25, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37021666/prevention-of-first-episode-psychosis-in-people-at-clinical-high-risk-a-randomized-controlled-multicentre-trial-comparing-cognitive-behavioral-therapy-and-clinical-management-plus-low-dose-aripiprazole-or-placebo-prevent
#11
JOURNAL ARTICLE
Andreas Bechdolf, Hendrik Müller, Martin Hellmich, Walter de Millas, Peter Falkai, Wolfgang Gaebel, Jürgen Gallinat, Alkomiet Hasan, Andreas Heinz, Birgit Janssen, Georg Juckel, Anne Karow, Seza Krüger-Özgürdal, Martin Lambert, Wolfgang Maier, Andreas Meyer-Lindenberg, Verena Pützfeld, Franziska Rausch, Frank Schneider, Hartmut Stützer, Thomas Wobrock, Michael Wagner, Mathias Zink, Joachim Klosterkötter
BACKGROUND: There is limited knowledge of whether cognitive-behavioral therapy (CBT) or second-generation antipsychotics (SGAs) should be recommended as the first-line treatment in individuals at clinical high risk for psychosis (CHRp). HYPOTHESIS: To examine whether individual treatment arms are superior to placebo and whether CBT is non-inferior to SGAs in preventing psychosis over 12 months of treatment. STUDY DESIGN: PREVENT was a blinded, 3-armed, randomized controlled trial comparing CBT to clinical management plus aripiprazole (CM + ARI) or plus placebo (CM + PLC) at 11 CHRp services...
April 6, 2023: Schizophrenia Bulletin
https://read.qxmd.com/read/36595095/a-systematic-review-of-interventions-in-the-early-course-of-bipolar-disorder-i-or-ii-a-report-of-the-international-society-for-bipolar-disorders-taskforce-on-early-intervention
#12
REVIEW
A Ratheesh, D Hett, J Ramain, E Wong, L Berk, P Conus, M A Fristad, T Goldstein, M Hillegers, S Jauhar, L V Kessing, D J Miklowitz, G Murray, J Scott, M Tohen, L N Yatham, A H Young, M Berk, S Marwaha
BACKGROUND: Given the likelihood of progressive illness in bipolar disorder (BD), it is important to understand the benefits and risks of interventions administered early in illness course. We conducted a systematic review of the effectiveness of interventions in the early course of BD I or II. METHODS: We completed a systematic search on MEDLINE, PsycINFO, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL and Google Scholar from 1/1/1979 till 14/9/2022...
January 3, 2023: International Journal of Bipolar Disorders
https://read.qxmd.com/read/36405896/therapeutic-management-of-buying-shopping-disorder-a-systematic-literature-review-and-evidence-based-recommendations
#13
Octavian Vasiliu
The prevalence of buying/shopping disorder (B/SD) has been increasing in the last two decades, and this disorder has a substantial negative impact on general functioning and quality of life. Therefore, a systematic review of the studies dedicated to the efficacy and tolerability of therapeutic interventions, both psychological and pharmacological, might help clinicians to decide on the most evidence-based treatment for these patients. In order to further increase the clinical usefulness of the current review, GRADE-based recommendations were formulated, where enough evidence was found to support such an approach...
2022: Frontiers in Psychiatry
https://read.qxmd.com/read/35900217/world-federation-of-societies-of-biological-psychiatry-wfsbp-guidelines-for-treatment-of-anxiety-obsessive-compulsive-and-posttraumatic-stress-disorders-version-3-part-ii-ocd-and-ptsd
#14
JOURNAL ARTICLE
Borwin Bandelow, Christer Allgulander, David S Baldwin, Daniel Lucas da Conceição Costa, Damiaan Denys, Nesrin Dilbaz, Katharina Domschke, Eric Hollander, Siegfried Kasper, Hans-Jürgen Möller, Elias Eriksson, Naomi A Fineberg, Josef Hättenschwiler, Hisanobu Kaiya, Tatiana Karavaeva, Martin A Katzman, Yong-Ku Kim, Takeshi Inoue, Leslie Lim, Vasilios Masdrakis, José M Menchón, Euripedes C Miguel, Antônio E Nardi, Stefano Pallanti, Giampaolo Perna, Dan Rujescu, Vladan Starcevic, Dan J Stein, Shih-Jen Tsai, Michael Van Ameringen, Anna Vasileva, Zhen Wang, Joseph Zohar
AIM: This is the third version of the guideline of the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders which was published in 2002 and revised in 2008. METHOD: A consensus panel of 34 international experts representing 22 countries developed recommendations based on efficacy and acceptability of the treatments. In this version, not only medications but also psychotherapies and other non-pharmacological interventions were evaluated, applying the same rigorous methods that are standard for the assessment of medication treatments...
February 2023: World Journal of Biological Psychiatry
https://read.qxmd.com/read/35894719/a-review-of-treatments-and-clinical-guidelines-for-perinatal-depression
#15
REVIEW
Maria McDonald, Jeanne Alhusen
Perinatal depression occurs in approximately 1 in 7 women and is considered the most common complication of pregnancy and childbearing. Management of perinatal depression may include a combination of nonpharmacological and pharmacological therapies depending on the severity of symptoms, the stage of gestation, and maternal preference. Healthcare providers are recommended to review current guidelines and provide information to women during pregnancy and postpartum regarding the risks and benefits of nonpharmacological and pharmacological treatment options for perinatal depression...
July 2022: Journal of Perinatal & Neonatal Nursing
https://read.qxmd.com/read/35862601/ce-original-research-cognitive-behavioral-therapy-for-symptom-management-in-treatment-resistant-schizophrenia
#16
REVIEW
Matilda Ryan, Dina Sattenspiel, Alexander Chianese, Helen Rice
BACKGROUND: Treatment-resistant schizophrenia (TRS) comes with significant medical comorbidities, including heart disease, liver disease, and diabetes-all of which contribute to higher mortality rates and shortened life expectancy. Second-generation antipsychotic medications do not consistently alleviate psychotic symptoms, especially among patients with TRS. Clozapine, the gold standard of pharmacological treatment for TRS, offers only partial relief for many patients. Additional treatment approaches, which include cognitive behavioral therapy (CBT), are often necessary...
August 1, 2022: American Journal of Nursing
https://read.qxmd.com/read/35735408/postdiction-in-visual-awareness-in-schizophrenia
#17
JOURNAL ARTICLE
Szabolcs Kéri
BACKGROUND: The mistiming of predictive thought and real perception leads to postdiction in awareness. Individuals with high delusive thinking confuse prediction and perception, which results in impaired reality testing. The present observational study investigated how antipsychotic medications and cognitive-behavioral therapy (CBT) modulate postdiction in schizophrenia. We hypothesized that treatment reduces postdiction, especially when antipsychotics and CBT are combined. METHODS: We enrolled patients with schizophrenia treated in a natural clinical setting and not in a randomized controlled trial...
June 20, 2022: Behavioral Sciences
https://read.qxmd.com/read/35661550/the-effect-of-treatment-on-insight-in-psychotic-disorders-a-systematic-review-and-meta-analysis
#18
REVIEW
Sean Phelan, Natasha Sigala
BACKGROUND: For people with a psychotic disorder lack of insight can be detrimental on their condition and recovery. For this reason, insight has been considered as a target for therapy. We conducted a systematic review of the literature on pharmacological, psychological and other treatments to test the hypothesis that these interventions could improve insight. METHODS: We performed a literature search (1970-2020) across the following databases: PubMed, EMBASE, PsychINFO, Medline and Web of Science...
June 2022: Schizophrenia Research
https://read.qxmd.com/read/35323098/serotonin-reuptake-inhibitor-cognitive-behavioural-therapy-second-generation-antipsychotic-combination-for-severe-treatment-resistant-obsessive-compulsive-disorder-a-prospective-observational-study
#19
JOURNAL ARTICLE
Antonio Tundo, Loretta Salvati, Luca Cieri, Viviana Balestrini, Daniela Di Spigno, Floriana Orazi, Marica Iommi, Roberta Necci
INTRODUCTION: Six in ten patients with obsessive-compulsive disorder (OCD) do not respond to the first-line treatments with serotonin reuptake inhibitor (SRI) or cognitive behavioural therapy including exposure and response prevention (CBT/ERP), and several do not respond to second-line treatments, i.e., SRI-second generation antipsychotic (SGA) or SRI-CBT/ERP augmentation. Evidence on third-line treatments is inconsistent. OBJECTIVE: We investigated the 1-year response to SRI-CBT/ERP-SGA combination in patients with severe treatment-resistant OCD, who failed to respond to SRI and to SRI-SGA or SRI-CBT/ERP augmentation...
March 24, 2022: International Journal of Psychiatry in Clinical Practice
https://read.qxmd.com/read/35123427/rtms-combined-with-cbt-as-a-next-step-in-antidepressant-non-responders-a-study-protocol-for-a-randomized-comparison-with-current-antidepressant-treatment-approaches
#20
JOURNAL ARTICLE
Iris Dalhuisen, Filip Smit, Jan Spijker, Iris van Oostrom, Eric van Exel, Hans van Mierlo, Dieuwertje de Waardt, Martijn Arns, Indira Tendolkar, Philip van Eijndhoven
BACKGROUND: Major depressive disorder (MDD) is one of the most common psychiatric disorders, however, current treatment options are insufficiently effective for about 35% of patients, resulting in treatment-resistant depression (TRD). Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive neuromodulation that is effective in treating TRD. Not much is known about the comparative efficacy of rTMS and other treatments and their timing within the treatment algorithm, making it difficult for the treating physician to establish when rTMS is best offered as a treatment option...
February 5, 2022: BMC Psychiatry
keyword
keyword
109528
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.